Please ensure Javascript is enabled for purposes of website accessibility Global Life Sciences Fund - Janus Henderson Investors
For investors in Singapore

Global Life Sciences Fund

By understanding the science and business of health care, the strategy invests in companies addressing unmet medical needs or improving health care efficiencies

ISIN
IE0009355771

NAV
USD 51.19
As of 2024/04/17

1-Day Change
USD -0.11 (-0.21%)
 As of 2024/04/17

Morningstar Rating

As of 2024/03/31

Overview

OBJECTIVE AND INVESTMENT POLICY

The Fund aims to provide capital growth over the long term.

More

The Fund invests at least 80% of its assets in shares (also known as equities) selected for their growth potential and with a life sciences orientation. The Fund may invest in companies of any size, in any country.

Less

Note: You should not make investment decisions based solely on marketing materials. You should read the Prospectus and the Product Highlights Sheet of the Fund for more details of the investment risks and seek independent professional advice where appropriate.

ABOUT THIS FUND

  • Looks to invest in companies addressing unmet medical needs or making the health care system more efficient
  • Aims to maintain a balanced portfolio across subsectors (pharmaceuticals, biotechnology, health care services, and medical devices)
  • An experienced team of specialists that seeks to understand the science and the business of health care

PORTFOLIO MANAGEMENT

Andy Acker, CFA

Andy Acker, CFA

Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, Ph.D., CFA

Daniel Lyons, Ph.D., CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.

Performance

Cumulative & Annualised Performance (%)
As of 2024/03/31
A2 USD (Net) A2 USD (With Sales Charge)* MSCI World Health Care NR
 
  Cumulative Annualised
1MO 3MO 6MO YTD 1YR 3YR 5YR 10YR Since Inception
2000/03/31
A2 USD (Net) 1.56 8.07 16.51 8.07 15.99 5.68 9.56 9.50 7.33
A2 USD (With Sales Charge)* -3.52 2.67 10.68 2.67 10.19 3.89 8.45 8.94 7.10
MSCI World Health Care NR 2.35 7.47 13.78 7.47 13.32 7.85 10.33 9.18 7.79
Past performance is not a guide to future performance. All performance data includes both income and capital gains or losses and reflects the deduction of any ongoing charges or other fund expenses.
*Performance with sales charge assume 5.00% initial sales charge/front-end load (FEL) applied.
© Morningstar 2024. All rights reserved. NAV-NAV, gross income reinvested where applicable.
Calendar Year Returns (%)
As of 2024/03/31
A2 USD (Net) MSCI World Health Care NR
2023 2022 2021 2020 2019
A2 USD (Net) 5.44 -4.35 4.72 23.41 27.06
MSCI World Health Care NR 3.76 -5.41 19.80 13.52 23.24
Calendar Year Returns (%)
Year A2 USD (Net) Index
2023 5.44 3.76
2022 -4.35 -5.41
2021 4.72 19.80
2020 23.41 13.52
2019 27.06 23.24
2018 2.01 2.51
2017 20.55 19.80
2016 -13.79 -6.81
2015 5.69 6.60
2014 32.75 18.10
2013 52.45 36.27
2012 22.47 17.54
2011 6.08 9.46
2010 6.04 2.41
2009 24.46 18.89
2008 -31.08 -21.50
2007 19.64 3.94
2006 -3.74 10.47
2005 9.89 9.00
2004 12.36 6.00
2003 25.55 19.50
2002 -31.32 -17.98
2001 -20.46 -13.24
2000 from 31/03/2000 16.80 25.65
Past performance is not a guide to future performance. All performance data includes both income and capital gains or losses and reflects the deduction of any ongoing charges or other fund expenses.
*Performance with sales charge assume 5.00% initial sales charge/front-end load (FEL) applied.
© Morningstar 2024. All rights reserved. NAV-NAV, gross income reinvested where applicable.
FEE INFORMATION
Initial Charge 5.00%
Annual Charge 1.50%
Ongoing Charge
(As of 2022/12/31) 		2.40%

Portfolio

Top Holdings (As of 2024/03/31)
% OF FUND
Eli Lilly & Co 7.08
UnitedHealth Group Inc 5.87
Novo Nordisk A/S 5.13
Merck & Co Inc 3.64
AstraZeneca PLC 3.57
AbbVie Inc 3.36
Sanofi SA 2.48
Boston Scientific Corp 2.30
Vertex Pharmaceuticals Inc 2.30
Abbott Laboratories 2.26
TOTAL 37.99
Sector Allocation % OF FUND % OF FUND (As of 2024/03/31)
Regional Allocation % OF FUND % OF FUND (As of March 31, 2024)

Documents

Related Insights

Our intellectual capital is readily available and central to our Knowledge Shared approach"
Related Insights
Why healthcare stocks could catch a break this election year
Apr 2, 2024
Timely & Topical

Why healthcare stocks could catch a break this election year

The sector has historically underperformed in the lead-up to U.S. presidential elections, but that may not be the case in 2024.

5 min read

Global Perspectives: Investing in the small- and midsize healthcare companies innovating for a graying world
Feb 21, 2024
Features & Outlooks

Global Perspectives: Investing in the small- and midsize healthcare companies innovating for a graying world

How healthcare’s small- and mid-cap companies could benefit from one of today’s key macroeconomic growth drivers: aging populations.

27 min read

Healthcare’s small- and mid-cap opportunities amid aging populations
Feb 13, 2024
Features & Outlooks

Healthcare’s small- and mid-cap opportunities amid aging populations

With populations in some of the largest economies quickly graying, innovative small- and mid-cap healthcare companies could deliver new growth opportunities for investors.

8 min read